2022 American Transplant Congress
Analysis of Induction Dose and Incidence of CMV Viremia in High Risk (HR; D+/R-) Renal Transplant Recipients
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Depleting induction puts patients at risk of opportunistic infections. Our protocol aims for 5-6mg/kg cumulative dose of antithymocyte globulin(ATG) divided over 4 doses. It…2022 American Transplant Congress
Single Cell And Spatial Transcriptomics Of Blood And Biopsies Reveals Enhanced Alloantigen Presenting Function And T-follicular Helper Cell (tfh) Expansion Early After Pediatric Liver Transplantation
*Purpose: We have previously reported enhanced B-cell presentation of donor antigen during early T-cell mediated liver transplant (LT) rejection.*Methods: To characterize B-cell related immunological mechanisms…2022 American Transplant Congress
Utility of a Holistic Molecular Paradigm for Kidney Biopsy in the Clinic
1Intermountain Medical Center, Murray, UT, 2CareDX, South San Francisco, CA
*Purpose: We report on the clinical utility of a serial dd-cfDNA (donor derived cell free DNA) monitoring coupled with Tissue Transcriptomics (Tr) and Histology (Hx)…2022 American Transplant Congress
A Novel Approach to Non-Invasive Multimodality Testing with Allosure and Allomap Predicts Microvascular Inflammation with High Accuracy in Kidney Transplant Recipients
University of Wisconsin, Madison, WI
*Purpose: The most prominent histologic lesion in antibody-mediated rejection (ABMR) is microvascular inflammation (MVI); however, its recognition and scoring can be challenging and poorly reproducible…2022 American Transplant Congress
Outcomes in Renal Transplant Recipients Receiving Pre-Transplant Financial Assistance Through the American Kidney Fund
*Purpose: Pre-transplant financial assistance for insurance premiums is available for eligible patients through the American Kidney Fund (AKF), but this funding ends within the first…2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…2022 American Transplant Congress
Month 1 Donor Derived Cell Free DNA Levels Predict Future Kidney Transplant Rejection
1Northwestern University, Chicago, IL, 2Transplant Nephrology, Northwestern University, Chicago, IL
*Purpose: The purpose of this study was to determine if donor-derived cell-free DNA (dd-cfDNA) can be used one-month post-transplant to predict later allograft rejection.*Methods: Retrospective…2022 American Transplant Congress
Recipient Treatment with Anti-CD122 mAb Prolongs Kidney Allograft Survival During Antibody-Mediated Rejection without Impacting NK Cell Activation within the Graft
Cleveland Clinic, Cleveland, OH
*Purpose: Dysregulated donor-specific antibody (DSA) responses are induced in B6.CCR5-/- mice transplanted with complete MHC mismatched kidney allografts and are required for rejection of the…2022 American Transplant Congress
Long-Term (>1 Year) Rejection Free Graft Survival of Kidney Xenografts with Triple Xenoantigen Knockout and Multiple Human Transgenes in Cynomolgus Monkeys
*Purpose: Pigs with deletion of 3 carbohydrate xenoantigens (triple knock-out, TKO) are expected to be optimal donors for human xenotransplantation. We have previously shown that…2022 American Transplant Congress
A New Algorithm Combining Donor Derived Cell-Free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology
1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2Natera, Inc., Austin, TX
*Purpose: Donor derived cell-free DNA (dd-cfDNA) has been shown to be associated with allograft rejection, both histological and molecular (JASN, in press). Clinically available dd-cfDNA…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 172
- Next Page »